HC Wainwright Has Bullish Outlook for Agenus FY2025 Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Agenus in a note issued to investors on Tuesday, November 11th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings per share of $2.09 for the year, up from their previous forecast of $0.03. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at $1.54 EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($1.69) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.61) EPS.

Other equities analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Agenus in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Agenus to a “hold” rating in a report on Tuesday, August 12th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Price Performance

Shares of Agenus stock traded down $0.03 during trading on Thursday, reaching $4.40. 85,988 shares of the company traded hands, compared to its average volume of 726,188. The firm has a market capitalization of $140.20 million, a PE ratio of -0.62 and a beta of 1.43. Agenus has a 1-year low of $1.38 and a 1-year high of $7.34. The company has a 50 day moving average price of $4.18 and a 200-day moving average price of $4.50.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The business had revenue of $30.24 million during the quarter, compared to analysts’ expectations of $80.39 million.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Apollon Wealth Management LLC grew its stake in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 5,000 shares in the last quarter. Traynor Capital Management Inc. bought a new position in Agenus in the 3rd quarter valued at $50,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Agenus in the second quarter worth $50,000. Jump Financial LLC purchased a new stake in shares of Agenus in the second quarter worth $55,000. Finally, Acadian Asset Management LLC purchased a new position in Agenus during the first quarter worth about $58,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.